A Premier Centre for Cutting Edge Cancer Research.
A dynamic research institute encompassing basic and translational studies, devoted to understanding the pathogenesis and treatment of cancer
CSI Singapore Clinches Multiple Awards at NCAM 2020 Digital Meeting
The 7th NCIS Annual Research Meeting (NCAM) 2020 recently concluded its first digital meeting, which took place from 22 - 25 July 2020.
Read More
Novel Digital Medicine Platform Offers New Hope for Lymphoma Patients
Researchers from CSI Singapore and NCIS recently harnessed the Quadratic Phenotypic Optimisation Platform (QPOP), an AI-driven digital medicine platform, to revolutionize the treatment for lymphoma.
Read More
(Blood, Jun 2020)
Lysine Acetyltransferase Tip60 Is Required for Hematopoietic Stem Cell Maintenance.
Read More
(Sci Adv, Jun 2020)
Suppression of Adenosine-To-Inosine (A-to-I) RNA Editome by Death Associated Protein 3 (DAP3) Promotes Cancer Progression.
Read More
(Blood, Jun 2020)
Hematopoietic Stem Cells Acquire Survival Advantage by Loss of RUNX1 Methylation Identified in Familial Leukemia.
Read More
Congratulations to Prof. Toshio Suda for being awarded the 2020 E. Donnall Thomas Lecture and Prize!
Prof. Suda will present his lecture at the 62nd ASH Annual Meeting and Exposition.
Read More
Giving to CSI
You can help us to shape the next generation of innovative cancer research
